AXSM Stock Risk & Deep Value Analysis
Axsome Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About AXSM Stock
We analyzed Axsome Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran AXSM through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
AXSM Risk Analysis & Red Flags
What Could Go Wrong
The PDUFA decision for AXS-05 (Auvelity for Alzheimer's agitation) on April 30, 2026, is a binary event. A rejection or significant delay could cause a substantial stock price decline (e.g., 30-50%+) as the market re-evaluates the growth thesis and the company's path to profitability.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
High
Red Flags
- ⚠
Vanguard's reported 0% ownership (post-internal realignment) warrants caution regarding institutional conviction.
- ⚠
The company is currently net loss-making and likely Free Cash Flow negative, making it reliant on successful commercialization of AXS-05 for future profitability.
- ⚠
No clear EPS estimates provided for future profitable quarters, making traditional fundamental valuation challenging.
Upcoming Risk Events
- 📅
Regulatory rejection or significant delay for AXS-05 (AD-agitation) PDUFA
- 📅
Slower-than-expected commercial uptake of Auvelity in new indications
- 📅
Unexpected competition or shifts in treatment paradigms
When to Reconsider
- 🚪
Regulatory rejection or significant delay for AXS-05 (AD-agitation).
- 🚪
Quarterly Auvelity sales growth significantly decelerates (e.g., below 20% YoY for MDD).
- 🚪
Cash balance drops below $150M without clear path to Free Cash Flow positivity or immediate financing.
Unlock AXSM Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Axsome Therapeutics Inc (AXSM) Do?
Market Cap
$9.39B
Sector
Healthcare
Industry
Biotechnology
Employees
816
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase III trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Visit Axsome Therapeutics Inc WebsiteInvestment Thesis
Axsome Therapeutics is positioned for significant growth driven by the imminent regulatory approval of Auvelity for Alzheimer's agitation, a massive underserved market. Combined with strong commercial execution for its existing CNS products and a healthy balance sheet, the company has the potential to transform into a leading CNS pharmaceutical player, justifying substantial long-term appreciation.
Is AXSM Stock Undervalued?
Unlock the full AI analysis for AXSM
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
AXSM Price Targets & Strategy
12-Month Target
$229.00
Bull Case
$280.00
Bear Case
$120.00
Valuation Basis
Based on 11.5x P/S applied to projected FY26 revenue of $1.02B (assuming 60% YoY growth post-AD agitation approval)
Entry Strategy
Consider dollar-cost averaging on dips to the $160-$170 range following PDUFA, as initial post-catalyst volatility may present opportunities.
Exit Strategy
Take partial profits at $229 and $280. Implement a stop-loss order if the stock closes below $150 (psychological support).
Portfolio Allocation
5% for aggressive risk tolerance (given high growth potential and regulatory event).
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is AXSM Financially Healthy?
Valuation
P/E Ratio
-43.84
Forward P/E
27.23
Price/Book
127.04
Price/Sales
16.72
Profitability
Gross Margin
91.86%
Operating Margin
-34.71%
Net Margin
-40.89%
Return on Equity
-155.77%
Revenue Growth
65.00%
EPS
$-4.66
Balance Sheet
Current Ratio
1.57
Quick Ratio
1.45
Debt/Equity
2.96
Cash Flow
Free Cash Flow
-$94.10M
EBITDA
-$187.95M
Other
Beta (Volatility)
0.43
Does AXSM Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
1 Identified
Axsome's moat is primarily built on intellectual property protection for its novel drugs. This provides a durable, though not indefinite, period of market exclusivity. Sustained efficacy and safety profiles, along with pipeline diversification, will be key to long-term durability.
Moat Erosion Risks
- •Potential patent challenges or expiration of key patents.
- •Emergence of superior or more cost-effective treatments from competitors.
- •Regulatory changes impacting drug pricing or market access.
AXSM Competitive Moat Analysis
Sign up to see competitive advantages
AXSM Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral to Bullish, driven by anticipation of key regulatory decision and strong revenue growth.
Institutional Sentiment
Positive, with recent analyst upgrades and high price targets, but some uncertainty from Vanguard's reported ownership shift.
Insider Activity (Form 4)
No specific Form 4 filings reported for buys/sells in last 90 days. No CEO/CFO activity flagged.
Options Flow
Normal options activity; no specific unusual activity reported.
Earnings Intelligence
Next Earnings
2026-05-04
Surprise Probability
Medium
Historical Earnings Pattern
Likely volatile due to biotech nature and the high impact of regulatory and pipeline news, rather than just financial results.
Key Metrics to Watch
Competitive Position
Top Competitor
Lundbeck (Rexulti in AD-agitation)
Market Share Trend
Gaining in MDD (0.2% antidepressant share with significant room for expansion); positioned to gain substantial market share in AD-agitation if approved.
Valuation vs Peers
No sector median or peer-specific valuation multiples provided for direct comparison, but analyst targets suggest a growth premium.
Competitive Advantages
- •Differentiated mechanism of action for Auvelity (NMDA receptor antagonist)
- •Strong gross margins (93%) on current products
- •Experienced commercial and regulatory team in CNS disorders
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive AXSM Stock Higher?
Near-Term (0-6 months)
- •PDUFA for AXS-05 (Auvelity for Alzheimer's agitation) on 2026-04-30
- •Q1 2026 Earnings Report on 2026-05-04
- •Sales force doubling to 600 reps by Q2 2026
Medium-Term (6-18 months)
- •Initial commercial ramp and sales figures for Auvelity in Alzheimer's agitation (post-approval)
- •Pipeline updates for AXS-17 (acquired via Baergic Bio)
Long-Term (18+ months)
- •Significant market share capture in the Alzheimer's agitation market
- •Potential for Auvelity label expansion into other CNS indications
- •Deepening of CNS pipeline with additional product candidates
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for AXSM?
- ✓
Successful commercial launch and revenue ramp of Auvelity in AD-agitation.
- ✓
Improvement in operating cash flow and progression towards net profitability.
- ✓
Continued strong organic growth rates for existing products (Auvelity MDD, Sunosi).
Bull Case Analysis
See what could go right with Premium
Competing with AXSM
See how Axsome Therapeutics Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Axsome Therapeutics Inc AXSM | $9.4B | 8.6 | -43.8 | $561.3M | -40.9% | 65.0% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Axsome Therapeutics Inc Makes Money
Axsome Therapeutics is a pharmaceutical company focused on developing and commercializing novel therapies for central nervous system (CNS) disorders. They primarily generate revenue by selling their approved drugs, such as Auvelity for major depressive disorder and Sunosi for narcolepsy/excessive daytime sleepiness, to patients through pharmacies. Their business model involves extensive research and development to discover new treatments, navigating rigorous regulatory approval processes to gain market access, and then building commercial infrastructure, including a large sales force, to market and distribute their products. Success hinges on drug efficacy, market adoption, and robust intellectual property protection.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Axsome Therapeutics Inc (AXSM)?
As of April 9, 2026, Axsome Therapeutics Inc has a DVR Score of 8.6 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Axsome Therapeutics Inc?
Axsome Therapeutics Inc's market capitalization is approximately $9.4B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Axsome Therapeutics Inc use?
AXSM is the ticker symbol for Axsome Therapeutics Inc. The company trades on the NGM.
What is the risk level for AXSM stock?
Our analysis rates Axsome Therapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of AXSM?
Axsome Therapeutics Inc currently has a price-to-earnings (P/E) ratio of -43.8. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Axsome Therapeutics Inc's revenue growing?
Axsome Therapeutics Inc has reported revenue growth of 65.0%. The company is showing strong top-line momentum.
Is AXSM stock profitable?
Axsome Therapeutics Inc has a profit margin of -40.9%. The company is currently unprofitable.
How often is the AXSM DVR analysis updated?
Our AI-powered analysis of Axsome Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 9, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for AXSM (Axsome Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.